Cell line name |
BT-474 EEI |
Synonyms |
BT474-EEI; BT474 EEI; BT-474 Exogenous Estrogen Independent |
Accession |
CVCL_AR96 |
Resource Identification Initiative |
To cite this cell line use: BT-474 EEI (RRID:CVCL_AR96) |
Comments |
Population: Caucasian. Derived from site: In situ; Breast; UBERON=UBERON_0000310. |
Sequence variations |
- Gene fusion; HGNC; 24618; AHCTF1 + HGNC; 736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line).
- Gene fusion; HGNC; 7609; MYO9B + HGNC; 9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line).
- Gene fusion; HGNC; 16173; DOK5 + HGNC; 17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line).
- Gene fusion; HGNC; 16651; MRPL45 + HGNC; 16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line).
- Gene fusion; HGNC; 13178; IKZF3 + HGNC; 12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line).
- Mutation; HGNC; 1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line).
|
Disease |
Invasive breast carcinoma of no special type (NCIt: C4194) |
Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
Hierarchy |
Parent: CVCL_0179 (BT-474) |
Sex of cell |
Female |
Age at sampling |
60Y |
Category |
Cancer cell line |
Publications | PubMed=19010901; DOI=10.1158/0008-5472.CAN-08-1776 Lewis Phillips G.D., Li G.-M., Dugger D.L., Crocker L.M., Parsons K.L., Mai E., Blattler W.A., Lambert J.M., Chari R.V.J., Lutz R.J., Wong W.L.T., Jacobson F.S., Koeppen H., Schwall R.H., Kenkare-Mitra S.R., Spencer S.D., Sliwkowski M.X. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68:9280-9290(2008) |
Cross-references |
Cell line databases/resources |
cancercelllines; CVCL_AR96
|
Encyclopedic resources |
Wikidata; Q54798463
|
Entry history |
Entry creation | 02-May-2016 |
Last entry update | 05-Oct-2023 |
Version number | 12 |
---|